Prof. Yen Choo is the Executive Director of co11ab and an Associate Professor of Stem Cell Science and Regenerative Medicine at Lee Kong Chian School of Medicine (LKC Medicine), a
joint medical school of Nanyang Technological University (NTU) and Imperial College London. He obtained a Ph.D. in Molecular Biology from the University of Cambridge and the MRC Laboratory of Molecular Biology under the supervision of Nobel laureate Sir Aaron Klug. He is a serial entrepreneur with over 20 years of C-level and Board experience in the biotechnology industry. He was the founder and CSO of Gendaq, a biotech company that developed the zinc finger DNA-binding technology now used for gene editing. He is the founder and Chairman of Plasticell, one of the UK’s pioneering stem cell and regenerative medicine companies. He was also the founder of Progenitor Therapeutics, a drug discovery company established jointly with GSK to discover medicines that regenerate tissues of the human body. He sits on the Board Oversight Committee of the Advanced Cell Therapy and Research Institute, Singapore (ACTRIS), and the Steering Committee for the UK Stem Cell Bank and for the Use of Stem Cell Lines which oversees UK embryonic stem cell research and the UK Stem Cell Bank. He works on the development of platform technologies for stem cell research and the development of cell and gene therapies.
Prof. Yen Choo is the Executive Director of co11ab and an Associate Professor of Stem Cell Science and Regenerative Medicine at Lee Kong Chian School of Medicine (LKC Medicine), a
joint medical school of Nanyang Technological University (NTU) and Imperial College London. He obtained a Ph.D. in Molecular Biology from the University of Cambridge and the MRC Laboratory of Molecular Biology under the supervision of Nobel laureate Sir Aaron Klug. He is a serial entrepreneur with over 20 years of C-level and Board experience in the biotechnology industry. He was the founder and CSO of Gendaq, a biotech company that developed the zinc finger DNA-binding technology now used for gene editing. He is the founder and Chairman of Plasticell, one of the UK’s pioneering stem cell and regenerative medicine companies. He was also the founder of Progenitor Therapeutics, a drug discovery company established jointly with GSK to discover medicines that regenerate tissues of the human body. He sits on the Board Oversight Committee of the Advanced Cell Therapy and Research Institute, Singapore (ACTRIS), and the Steering Committee for the UK Stem Cell Bank and for the Use of Stem Cell Lines which oversees UK embryonic stem cell research and the UK Stem Cell Bank. He works on the development of platform technologies for stem cell research and the development of cell and gene therapies.